Central European Journal of Immunology is a premier publication dedicated to advancing the field of immunology and allergy research. Established in 1996 and published by TERMEDIA PUBLISHING HOUSE LTD, this open access journal has consistently provided a platform for innovative research and comprehensive reviews since its transition to open access in 2002. With an ISSN of 1426-3912 and E-ISSN of 1644-4124, it embraces a global readership while being rooted in Poland. The journal, with a notable Q3 ranking in both the categories of immunology and allergy in 2023, positions itself within the competitive landscape of scientific discourse, as reflected in its Scopus rankings. Designed for researchers, professionals, and students, the Central European Journal of Immunology not only disseminates significant findings but also fosters collaboration and innovation in the immunological sciences, making it a vital resource for those seeking to stay current in this rapidly evolving field.

Nature Reviews Gastroenterology & Hepatology is a premier academic journal published by NATURE PORTFOLIO, specializing in the vital fields of gastroenterology and hepatology. With an impressive impact factor and categorized in Q1 for both disciplines, this journal ranks at the top of its field, with Scopus rankings placing it in the 99th percentile for gastroenterology and hepatology. The journal aims to provide critical reviews that synthesize the latest research findings, clinical practices, and breakthroughs, catering to researchers, healthcare professionals, and students alike. With its wide-ranging access options, it promotes the dissemination of knowledge essential for advancements in understanding digestive and liver disorders. The journal has been committed to academic excellence since its convergence in 2009, continuing to shape the future of gastroenterological and hepatological research through rigorous peer-reviewed content.

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

EXERCISE IMMUNOLOGY REVIEW, published by W W F VERLAGSGESELLSCHAFT GMBH, stands as a premier journal within the realms of Immunology, Medicine, and Sports Science. With an impressive Q1 ranking in these fields as of 2023, it is recognized for its significant contributions to understanding the interplay between physical activity and immune function. The journal, which has been publishing since 1996 and continues to evolve through 2024, serves as an essential resource for researchers, professionals, and students eager to explore cutting-edge findings and discussions. Although it is not an open access publication, its content is accessible through institutional subscriptions and individual purchases, ensuring its reach across a global audience. As the journal consistently ranks in the 96th percentile in General Medicine on Scopus, it underscores its vital role in advancing the dialogue on how exercise influences health and disease management.

PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

JOURNAL OF CLINICAL INVESTIGATION is a premier scholarly journal published by the American Society for Clinical Investigation, dedicated to advancing the field of clinical research and medicine since its inception in 1945. With an impressive impact factor and ranked Q1 in the field of Medicine (miscellaneous), it stands out as a leading source of high-quality research, reflecting its exceptional position in Scopus ranking as #13 out of 636 in General Medicine, placing it in the 98th percentile. The journal focuses on groundbreaking studies that explore the underlying mechanisms of human disease, facilitating a deeper understanding that drives clinical practice and innovation. Although it is not an open-access journal, the insights and findings published in this esteemed journal are essential reading for researchers, healthcare professionals, and students aspiring to contribute to the dynamic landscape of clinical investigation. Published in the United States, it continues to shape the dialogue and advancement within the medical community through its rigorous peer-review process and commitment to excellence.

CELLULAR IMMUNOLOGY is a prestigious journal published by Academic Press Inc. Elsevier Science, dedicated to advancing the field of immunology. Established in 1970 and converging ongoing research up to 2024, this journal has carved out a significant niche within the academic community, boasting a notable Q2 ranking in the Immunology category and holding a respectable 67th percentile ranking within Scopus for its contributions to the disciplines of Immunology and Microbiology. The journal serves as a vital platform for disseminating high-quality research, reviews, and methodologies that elucidate the intricacies of cellular immune responses, thereby benefiting researchers, professionals, and students alike. Although it does not offer open access, the journal's impact is evidenced by its comprehensive coverage of pioneering studies and ongoing developments in the immunological sciences, positioning it as an essential resource for those seeking to deepen their understanding and engage with the latest findings in cellular immunology.

INFLAMMATION RESEARCH, published by SPRINGER BASEL AG, serves as a pivotal journal in the fields of Immunology and Pharmacology, with notable rankings of Q2 in Immunology and Q1 in Pharmacology as of 2023. With an ISSN of 1023-3830 and an E-ISSN of 1420-908X, this esteemed journal, located in Basel, Switzerland, has been at the forefront of advancing our understanding of inflammatory processes since its inception in 1995. Covering research trends and breakthroughs until 2024, it significantly contributes to both the theoretical frameworks and practical applications within its discipline, boasting a strong Scopus ranking of #40/313 in Pharmacology and #56/236 in Immunology, placing it in the top percentiles for its field. Although it does not offer Open Access options, the journal remains an invaluable resource for researchers, professionals, and students committed to unraveling the complexities of inflammation and its implications in health and disease.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

The International Journal of Inflammation, published by HINDAWI LTD, serves as a vital resource within the field of Immunology and Allergy. With an established Open Access policy since 2010, this journal provides unrestricted access to cutting-edge research, fostering collaboration and dissemination of knowledge among researchers, professionals, and students. The journal’s ISSN is 2090-8040 and E-ISSN 2042-0099. Situated in the United States with administrative offices in England, it has consistently contributed to the academic community, evidenced by its ranking in the Q3 category for 2023, reflecting its significant presence in the field. Covering a wide range of topics from the molecular basis of inflammation to clinical implications and treatment strategies, the journal engages with the latest developments and current debates. With a Scopus rank of 145 out of 233 in the category of Medicine, its percentile rank of 37th indicates its influence and relevance in contemporary research. As the journal continues to evolve from its convergence years spanning from 2012 to 2024, it remains committed to advancing knowledge and innovation in inflammation research.